Sanjeev Khindri Sells 1,185 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,185 shares of the company’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $84,739.35. Following the transaction, the insider directly owned 65,947 shares in the company, valued at $4,715,869.97. This represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sanjeev Khindri also recently made the following trade(s):

• On Monday, June 8th, Sanjeev Khindri sold 4,134 shares of Liquidia stock. The stock was sold at an average price of $65.46, for a total value of $270,611.64.

Liquidia Trading Up 1.6%

Shares of LQDA opened at $77.75 on Thursday. Liquidia Corporation has a fifty-two week low of $14.04 and a fifty-two week high of $82.96. The business has a 50-day moving average of $67.08 and a 200 day moving average of $47.81. The firm has a market cap of $6.91 billion, a P/E ratio of 555.40 and a beta of 0.55. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue for the quarter was up 4187.1% on a year-over-year basis. As a group, research analysts forecast that Liquidia Corporation will post 3.02 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LQDA. Wall Street Zen lowered shares of Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Bank of America restated a “neutral” rating and set a $79.00 target price (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Wells Fargo & Company raised their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Needham & Company LLC lifted their price target on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $68.88.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s YUTREPIA patent case appears to be turning more favorable, and the company is also being highlighted for expanding its patent position around the drug. That improves the outlook for protecting its pulmonary hypertension franchise and supports the bullish case for the stock. Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
• Neutral Sentiment: Brokerage coverage remains constructive overall, with Liquidia receiving a consensus “Moderate Buy” rating from analysts. That supports the stock’s longer-term outlook, but it is not a new catalyst on its own. Liquidia Corporation (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: Several insiders, including the CEO, CFO, general counsel, CAO, and others, disclosed stock sales at about the same price level. The trades were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, but the size and number of sales may still raise some investor caution. SEC filing – Roger Jeffs sale

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LQDA. Farallon Capital Management LLC raised its position in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC bought a new stake in Liquidia during the third quarter valued at $38,887,000. MPM Bioimpact LLC grew its position in Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in Liquidia during the third quarter worth about $12,571,000. Finally, Bank of America Corp DE increased its stake in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).